



January 17, 2014

PerkinElmer Introduces a Pre-Clinical High-Throughput Bioluminescence Small Animal Imaging System

SUMMARY: PerkinElmer introduces the [IVIS® SpectrumBL](#), developed to enable the pharmaceutical and biotech industries to improve efficiencies in pre-clinical imaging studies by increasing in vivo throughput for drug efficacy, safety and toxicology.

The IVIS SpectrumBL high-throughput 2D and 3D optical imaging system is currently the only system that can simultaneously image up to 10 mice with full gas anesthesia incorporation along with ultra-high sensitivity to support bioluminescence, chemiluminescence and Cerenkov radioisotopic imaging. PerkinElmer's leading optical imaging technology facilitates non-invasive longitudinal monitoring of disease progression, cell trafficking and gene expression patterns in living animals to enable customers to quantitatively evaluate drug efficacy. The IVIS SpectrumBL features a 5 and a 10 mouse anesthesia manifold for larger cohorts, offering robust in vivo data, as well as significantly increasing the potential number of compounds that can be screened in vivo in early stages of pre-clinical drug discovery.

About PerkinElmer, Inc.

PerkinElmer, Inc. is a global leader focused on improving the health and safety of people and the environment. The company reported revenue of approximately \$2.1 billion in 2012, has about 7,600 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com.

Media Contact:

Anna Christensen
Director of Marketing- In Vivo Imaging, PerkinElmer
Email: anna.christensen@perkinelmer.com